Eli Lilly's first-quarter 2026 results showcased a significant surge in profitability, primarily driven by its powerhouse GLP-1 medications for diabetes and weight loss.
The company delivered an impressive performance, with revenues of $19.8 billion and adjusted earnings per share (EPS) of $8.55, beating market expectations by 12% and 24%, respectively. The stars of the show were Mounjaro and Zepbound, which together generated $12.82 billion. This single franchise accounted for nearly two-thirds of total sales and was responsible for an estimated 94% of the company's year-over-year revenue growth, cementing its role as Lilly's core profit engine.
This success story is built on a few key pillars: accelerating demand, navigating complex market access, expanding production capacity, and innovating to broaden the market. Let's break down how these factors came together.
First, Lilly has adeptly managed challenges from insurance intermediaries. While major Pharmacy Benefit Managers (PBMs) like CVS Caremark have tried to limit access by excluding Zepbound from their standard coverage lists, Lilly countered strategically. By strengthening its direct-to-consumer platform, LillyDirect, and launching programs like Employer Connect, the company created alternative pathways for patients to get their medications, effectively bypassing some of the PBM roadblocks and sustaining strong sales volume.
Second, you can't sell what you can't make. The demand for these drugs is enormous, and a key part of Lilly’s story is its massive investment in manufacturing. The company has been pouring billions into new and expanded facilities in Indiana, Pennsylvania, and other U.S. sites. This aggressive build-out signaled to investors that Lilly is serious about meeting demand, giving credibility to its ambitious revenue forecast of $80–$83 billion for the year. This quarter's strong results confirm that production is successfully scaling up.
Finally, Lilly isn't just scaling its current products; it's expanding the entire category. The recent FDA approval of Foundayo, its new once-daily oral GLP-1 pill, is a potential game-changer. An effective pill removes the barrier for patients who are hesitant to use injectables, significantly widening the potential patient pool. Its immediate availability through LillyDirect further streamlines access, creating a powerful funnel to bring new users into Lilly's ecosystem.
- GLP-1 (Glucagon-like peptide-1) agonists: A class of medications that mimic a natural hormone to help control blood sugar, reduce appetite, and promote weight loss.
- PBM (Pharmacy Benefit Manager): A third-party company that acts as an intermediary between insurance plans, pharmaceutical companies, and pharmacies to manage prescription drug benefits.
- EPS (Earnings Per Share): A company's profit divided by the number of its outstanding common stock shares, indicating profitability on a per-share basis.